News | October 19, 2011

Siemens, UC Davis Partner to Establish PET Radiopharmaceutical Facility

October 19, 2011 — University of California Davis (UC Davis) Health System, Petnet Solutions Inc. and Northern California PET Imaging Center (NCPIC) announced a partnership to establish a radiochemistry research and training facility on the university’s Sacramento campus. The facility will also produce radiopharmaceutical products used in positron emission tomography (PET) scans. Petnet Solutions is a wholly owned subsidiary of Siemens Medical Solutions USA Inc.

“This exciting partnership brings together under one roof the basic science, clinical and commercialization arms of molecular imaging,” said Claire Pomeroy, UC Davis vice chancellor for human health sciences and dean of UC Davis School of Medicine. “It positions UC Davis more competitively for federal grants and it benefits the local economy by expanding business opportunities in medical technology.”

Under the terms of the partnership, 12,000 square feet of available space will be used to house state-of-the-art equipment and research laboratories. Petnet plans to set up manufacturing and distribution operations in part of the space. NCPIC anticipates creating a scale-up laboratory for biomarker production. UC Davis will establish laboratories for research scientists and trainees.

The multimillion-dollar project will include installation of two medical cyclotrons for the production of high-demand PET radioisotopes now utilized in clinical applications around the world. The most commonly used PET radioisotopes have a short radioactive half-life and are often usable for only a few minutes to hours; for this reason, close proximity to the new manufacturing and distribution facility benefits UC Davis’ research activities and clinical care needs throughout the Sacramento region.

Julie Sutcliffe, associate professor in the departments of biomedical engineering and hematology and oncology at UC Davis, will oversee the new research and training program; it is aimed at developing specialized molecular imaging agents to target diseases related to oncology, neurology and cardiology. The laboratory will be an important training site for scientists from around the country interested in creating new compounds and technologies to advance the field of molecular imaging.

“One of our key goals is to bring much greater precision to the diagnosis and treatment of disease,” said Sutcliffe, who specializes in cancer imaging research and serves as director of radiochemistry for the UC Davis Center for Molecular and Genomic Imaging. “Having a cutting-edge commercial production facility right on the other side of the wall from our research laboratory allows immediate access to the infrastructure and tools we need to advance patient care and health, and it will provide unique opportunities to commercialize and distribute novel compounds we discover or develop.”

Sutcliffe and her team often work with the short-lived radioactive imaging agents —called “radiotracers” — that are used in PET scans to obtain high-contrast images of diseased tissues. The tracers, for example, make cancerous tissues glow in the scanner’s computer-generated, 3-D images.

“PET scans are highly informative, but there is a critical need for even more specific visualization of biological processes,” said Sutcliffe, whose research focuses on the development and screening of targeted molecular imaging agents for in vivo imaging with PET. “This collaboration will help us develop innovative compounds and techniques that can be moved rapidly from the laboratory bench to a patient’s bedside, enabling us to truly realize PET’s full potential.”

As part of the agreement, Petnet will provide new imaging biomarkers for clinical trials and create the potential for a pipeline for commercialization of imaging biomarkers developed by UC Davis scientists. Its goal is to advance a new paradigm for molecular imaging through research and collaboration with top universities and teaching hospitals around the country.

The Northern California PET Imaging Center plans to use isotopes and radiopharmaceuticals from the new facility for patient diagnostics and clinical trials at its existing Sacramento clinic. The center was originally established as a joint effort between Sutter Health Sacramento and CHW Healthcare, Sacramento,

In addition to research and clinical care benefits, the partnership fits well with the economic development vision of the Sacramento Area Regional Technology Alliance and its medical technology program, MedStart.

For more information: www.norcalscans.org

Related Content

FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Novel PET Agent Could Help Guide Therapy for Brain Diseases

Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland

News | PET Imaging | April 10, 2018
Researchers have developed a new imaging agent that could help guide and assess treatments for people with various...
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
Overlay Init